Single-center, Open-label Study With 14C-radiolabeled Cenerimod to Investigate the Mass Balance, Pharmacokinetics, and Metabolism Following Single Oral Administration to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 16 May 2017
At a glance
- Drugs Cenerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 13 Jan 2017 Status changed from active, no longer recruiting to completed.
- 21 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 30 Sep 2016 New trial record